Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
MRNA has added another 3% this week, closing Monday at $203.21, and the gap between where the stock is trading and where the Street says it should be has widened to a level that now defines the entire investment case.
Short sellers have continued their exit at a pace that was unimaginable six weeks ago. The position has fallen to 28.7 million shares, down nearly 6% on the week and 43% over the past month. At the end of August, shorts held more than 51 million shares. They now hold fewer than 29 million, equivalent to 7.3% of the free float. That is still a meaningful overhang, but the direction of travel is unambiguous: the short community has been cutting steadily since mid-September, and the data shows no sign of a pause. Borrow conditions offer no friction to that exit. Availability has expanded to roughly 1,195%, the loosest it has been this year by a wide margin, up 48% on the week alone. The 52-week low in availability was 196%, which gives a sense of how completely the squeeze dynamic from August has reversed. Cost to borrow ticked up 12% on the week to 0.47%, but remains trivially low in absolute terms. The options market is mildly defensive, with the put/call ratio at 1.14, just above its 20-day average of 1.10, a z-score of 0.79. That is not extreme. Options traders are not screaming caution; they are modestly cautious.
The Street remains deeply split, and if anything the gap is widening. The consensus is Hold, with 15 analysts there and two at Sell and none on record at Buy in the consensus tally, though Argus Research did upgrade to Buy with a $180 target in late August. The mean price target sits at $120.67, which implies roughly 41% downside from the current price. Citigroup's Geoff Meacham downgraded to Sell on September 30, raising his target to $80 from $60, still implying more than 60% downside. Goldman Sachs is Neutral at $120. JP Morgan has an Underweight at $77. Morgan Stanley sits at Equal-Weight at $89. Barclays raised its target to $125 on August 24, also at Equal-Weight. UBS went to $150 in August. The bulls within that group accept a smaller loss relative to the current price but still see meaningful downside, which is a telling detail. No major firm with a current target is calling for upside from $203. The valuation picture confirms why. Price-to-book has moved to 17.7, up more than 5 points over the past month, while the underlying earnings picture remains negative. The forward EPS year-on-year improvement factor ranks in the 89th percentile, which sounds constructive until you note the ORTEX stock score flags that reflects a low base rather than a structural earnings recovery.
On the ownership side, FMR LLC (Fidelity) has grown its position to 12.96% of shares, adding more than 6 million shares in the most recently reported quarter. Capital Research and Management added 3.6 million shares, taking its stake to 5.58%. BlackRock added nearly 1 million shares. The institutional picture suggests that even as analysts uniformly see downside, some of the largest active managers have been building. The insider picture is less constructive. President Stephen Hoge sold roughly 80,500 shares across September 14 and 15, raising around $11.7 million in open-market sales. CFO James Mock sold 34,836 shares on September 10 for roughly $4.7 million. All these transactions were conducted under pre-arranged 10b5-1 plans, which reduces their signal value considerably, but the net insider position over 90 days is a sale of 671,000 shares worth approximately $49 million.
Moderna's next earnings event falls on November 5, one month away. The two most recent quarterly prints produced a one-day gain of 5.2% in August and a one-day loss of 4.8% in late July, so the market has swung in both directions around recent releases. With analysts uniformly below the current price, earnings will arrive as a direct test of whether the operating trajectory can begin to close that gap, or confirm the bears' central argument that the stock has run far ahead of the fundamentals.
See the live data behind this article on ORTEX.
Open MRNA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
